• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·TECH
Held by 3 Gurus
Share

Bio-Techne Corporation Stocks

$ 70.9Last Updated 29.06.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

$ 11.10B

$ 70.9
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Latest news

26.06.2026 15:38

Morning in New York: Indices Searching for Direction

17.04.2025 21:00

Royce spotlights small caps to invest in during a bear market

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of TECH is 68 and suggests 3.64% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to dec

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.07.2026 04:53

Shutterstock's stock plummeted nearly 30% after Getty Images called off its merger with the company

01.07.2026 02:13

Nike's earnings and revenue exceeded expectations. Why did its stock price fall?

01.07.2026 01:24

The Nasdaq had its best quarter since 2020, while the Dow posted its strongest first half in five years. What's next?

01.07.2026 00:45

The issuer of the USDC stablecoin has collapsed: Visa and Mastercard are creating a competing token

30.06.2026 23:40

Amazon will be the first among the cloud giants to invest $1 billion in its AI engineering division

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026